AgomAb Therapeutics NV (AGMB) Stock Price, News & Analysis
Why is AGMB Stock Down Today?
What Changed
Price Move History
- Daily moves over 5%
- 47 150 sessions, February 6, 2026 to September 11, 2026
- Largest daily move
- +29% close of June 29, 2026
Company Description
Agomab Therapeutics NV (AGMB) develops disease-modifying therapeutics for fibro-inflammatory, immunology, and inflammatory diseases. The company is a clinical-stage biopharmaceutical issuer headquartered in Antwerp, Belgium, and its American Depositary Shares trade on the Nasdaq Global Select Market under the symbol AGMB. Each ADS represents one common share of Agomab.
Agomab's research and development model centers on chronic fibrotic indications and therapies designed to target established biological pathways. Its product candidates use small-molecule and antibody approaches, including organ-restricted strategies intended to focus activity in affected tissues. The company describes its program focus as resolving fibro-inflammation and restoring organ function in diseases associated with fibrosis.
The company's disclosed pipeline includes ontunisertib, also known as AGMB-129, and AGMB-447. Ontunisertib is being developed in fibrostenosing Crohn's disease, a fibrotic complication of inflammatory bowel disease. AGMB-447 is an investigational inhaled, lung-restricted small molecule inhibitor of ALK5, also referred to as TGFβR1, in development for idiopathic pulmonary fibrosis. Agomab has reported U.S. composition-of-matter patent coverage for AGMB-447.
As a development-stage biopharmaceutical company, Agomab's operating activity is focused on pre-commercial research and clinical development rather than commercial product sales. Its recurring corporate disclosures address clinical-program progress, intellectual-property protection, regulatory interactions, research and development spending, financing activity, and governance matters. Agomab completed its initial public offering of ADSs in February 2026, establishing AGMB as a publicly traded foreign private issuer in the United States.
Stock Performance
AgomAb Therapeutics NV (AGMB) closed at $13.06 on September 11, 2026. Over the past month, the price has lost 12.1%.
AGMB Metrics & Rankings
Price returns through September 11, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
AgomAb Therapeutics NV has 10 recent news articles, with the latest published today. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. Key topics include management, conferences, earnings, IPO, offering. View all AGMB news →
SEC Filings
AgomAb Therapeutics NV has filed 5 recent SEC filings, including 5 Form 6-K. The most recent filing was submitted on September 11, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all AGMB SEC filings →
Financial Highlights
Upcoming Events
Cantor Healthcare Conference
H.C. Wainwright Conference
Morgan Stanley Conference
AgomAb Therapeutics NV has 3 upcoming scheduled events. Investors can track these dates to stay informed about potential catalysts that may affect the AGMB stock price.
Short Interest History
Short interest in AgomAb Therapeutics NV (AGMB) currently stands at 941.1 thousand shares, down 21.9% from the previous reporting period, representing 2.4% of the float. Since February 2026, short interest has increased by 697.3%. This relatively low short interest suggests limited bearish sentiment. The 7.7 days to cover indicates moderate liquidity for short covering.
Days to Cover History
Days to cover for AgomAb Therapeutics NV (AGMB) currently stands at 7.7 days, down 58.7% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The days to cover has increased 674% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 18.7 days.
AGMB Company Profile & Sector Positioning
AgomAb Therapeutics NV (AGMB) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Agomab Therapeutics (AGMB) reports that shareholders approved all resolutions at its Special and Extraordinary General Shareholders' Meeting held on September 11, 2026.
Approvals include the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Board of Directors and the consolidation and split adjustment of outstanding pre-IPO warrants. The warrant changes align these instruments with the share split implemented in connection with Agomab's IPO in February 2026. Meeting materials, including biographies of the new Board members, are available on the company’s website.